Edwards Lifesciences Announces Schedule of Activities at TCT 2007

IRVINE, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW) , a world leader in products and technologies to treat advanced cardiovascular disease, today announced its schedule of activities for the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, from Oct. 20 through 25 in Washington, D.C.

Edwards will also host an analyst luncheon on Wednesday, Oct. 24, at 12:00 p.m. EDT. The featured speakers at the luncheon will be Augusto Pichard, M.D., Professor of Medicine and Director of the Cardiac Catheterization Laboratories, Washington Center Hospital, Washington, D.C., and Alex Powell, M.D., Interventional Radiologist, Baptist Cardiac and Vascular Institute, Miami, Fla.

Dr. Pichard will discuss his experiences with the Edwards SAPIEN transcatheter aortic heart valve and the RetroFlex transfemoral delivery system. He will also provide his perspective on the potential this valve replacement technology has in treating high-risk patients suffering from severe aortic stenosis.

Dr. Powell will discuss the one-year results from the RESILIENT trial, the landmark randomized study of the Edwards LifeStent Self-Expanding Stent for the treatment of peripheral vascular disease in the superficial femoral artery (SFA).

A live webcast of the presentation will be available on the Edwards investor relations website at http://www.edwards.com/InvestorRelations/EventCalendar.htm from 12:30 to 1:30 p.m. EDT. An archived version of the webcast will be available later that day on the Edwards investor relations website in the News and Events section.

In addition to the analyst luncheon, the TCT program will include a number of clinical presentations featuring several of Edwards' interventional cardiovascular technologies. Among the presentations are (all times EDT):

    Sunday, Oct. 21
    --  The Valvular Heart Disease Summit -- 8:00 a.m. to 7:00 p.m., Room
        202B, co-sponsored by Edwards.  The summit will cover topics including
        mitral regurgitation therapies, transcatheter mitral valve repair and
        replacement, transcatheter pulmonic valve replacement, aortic stenosis
        and new devices.  Presentations during the summit include: an overview
        of Edwards' transcatheter heart valve replacement program, an update
        on the status of the PARTNER pivotal trial for this device and interim
        results from the EVOLUTION feasibility study, which utilizes Edwards'
        MONARC system, a device intended to treat functional mitral
        regurgitation in heart failure patients.

    Monday, Oct. 22
    --  Advanced Endovascular Techniques for the Treatment of Infrainguinal
        Disease -- 7:00 a.m. to 8:00 a.m., Room 149AB, supported through an
        educational grant by Edwards.  The breakfast meeting will address
        techniques and technologies for the treatment of infrainguinal
        disease, as well as adjunct therapies.

    Tuesday, Oct. 23
    --  "Blockbuster" Trial of the Day: RESILIENT -- 11:00 a.m. to 12:00 p.m.,
        Main Arena, Ballrooms ABC, Level 3.  Presentations will address the
        one-year results from the RESILIENT trial, the landmark randomized
        study of the Edwards LifeStent Self-Expanding Stent in the SFA.
    --  Hot Topics 2007/2008: Regulatory Pathways for Percutaneous Aortic
        Valves -- 2:15 p.m. to 2:45 p.m., Room 207AB. Jodi J. Akin, Edwards
        Lifesciences' vice president of clinical affairs, Heart Valve Therapy,
        presents the industry perspective in a discussion with representatives
        from the U.S. Food and Drug Administration, academia and industry
        about clinical studies and regulatory approval for percutaneous
        technology. Stanton Rowe, Edwards' corporate vice president, Advanced
        Technology, will also serve as one of the discussants.

    Wednesday, Oct. 24
    --  Transcatheter Heart Valve Fundamentals from Science to Patient:
        Edwards SAPIEN Transcatheter Heart Valve -- 7:00 a.m. to 8:00 a.m.,
        Room 152A.  The breakfast meeting will provide an overview of the
        Edwards SAPIEN transcatheter valve's design, development and
        performance in patients.

Representatives from Edwards will also be in the exhibition area at booth 5041 on level two.

About Edwards Lifesciences

Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards, Edwards SAPIEN, MONARC and RetroFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and is registered in the United States Patent and Trademark Office.